| 106614-1 | Infectious path pnl Fld NAA+n-prb | 2 |
| 106623-2 | Hospice Outcomes and Patient Evaluation (HOPE) Admission v1.0:-:RptPeriod:^Patient:-:CMS Assessment | 7 |
| 106624-0 | Hospice Outcomes and Patient Evaluation (HOPE) v1.0:-:RptPeriod:^Patient:-:CMS Assessment | 4 |
| 106625-7 | Hospice Outcomes and Patient Evaluation (HOPE) Discharge v1.0:-:RptPeriod:^Patient:-:CMS Assessment | 2 |
| 106636-4 | CPR Preference:-:RptPeriod:^Patient:-:CMS Assessment | 4 |
| 106638-0 | Other Life-Sustaining Treatment Preferences:-:RptPeriod:^Patient:-:CMS Assessment | 4 |
| 106641-4 | Hospitalization Preference:-:RptPeriod:^Patient:-:CMS Assessment | 4 |
| 106644-8 | Spiritual or Existential Concerns:-:RptPeriod:^Patient:-:CMS Assessment | 4 |
| 106663-8 | Pain Screening:-:RptPeriod:^Patient:-:CMS Assessment | 8 |
| 106671-1 | Comprehensive Pain Assessment:-:RptPeriod:^Patient:-:CMS Assessment | 6 |
| 106675-2 | Screening for Shortness of Breath:-:RptPeriod:^Patient:-:CMS Assessment | 6 |
| 106679-4 | Treatment for Shortness of Breath:-:RptPeriod:^Patient:-:CMS Assessment | 4 |
| 106682-8 | Symptom Impact:-:RptPeriod:^Patient:-:CMS Assessment | 32 |
| 106685-1 | Symptom Impact Screening:-:RptPeriod:^Patient:-:CMS Assessment | 8 |
| 106704-0 | Symptom Follow-up Visit:-:RptPeriod:^Patient:-:CMS Assessment | 12 |
| 106708-1 | SFV Symptom Impact:-:RptPeriod:^Patient:-:CMS Assessment | 32 |
| 106715-6 | Bowel Regimen:-:RptPeriod:^Patient:-:CMS Assessment | 8 |
| 106717-2 | PRN Opioid:-:RptPeriod:^Patient:-:CMS Assessment | 8 |
| 106718-0 | Scheduled Opioid:-:RptPeriod:^Patient:-:CMS Assessment | 8 |
| 106732-1 | Benzodiazepines Pnl SerPlBld Cfm | 1 |
| 106762-8 | HIV prEP pnl SerPl | 5 |
| 106793-3 | Cntinus gluc monitoring time in rng pnl | 6 |
| 106797-4 | Peanut comp aller IgE Ab pnl Ser IA | 9 |
| 106804-8 | FGS panel | 7 |
| 106875-8 | Perceived stress scale-10:-:RptPeriod:^Patient:-:PSS-10 | 12 |
| 106881-6 | PROMIS Item Bank v1.0 - Emotional Distress - Anxiety - Short Form 8a:-:Pt:^Patient:-:PROMIS | 10 |
| 106904-6 | Perceived stress scale-14:-:RptPeriod:^Patient:-:PSS-14 | 16 |
| 106925-1 | Intimate Partner Violence 4:-:RptPeriod:^Patient:-:IPV-4 | 5 |
| 106933-5 | Hospice Outcomes and Patient Evaluation (HOPE) Update Visit v1.0:-:RptPeriod:^Patient:-:CMS Assessment | 5 |
| 106935-0 | Administrative information HOPE:-:RptPeriod:^Patient:-:CMS Assessment | 78 |
| 107095-2 | Medical device description panel | 1 |
| 107101-8 | Billing encounter information | 1 |
| 107104-2 | PROMIS Pediatric Item Bank GenPop v3.0 - Depressive Symptoms - Short Form 8a:-:Pt:^Patient:-:PROMIS | 11 |
| 107107-5 | MNA_SF 3MO Reported.MNA-SF | 9 |
| 107120-8 | Waveform observation information panel | 1 |
| 107125-7 | Waveform information panel | 1 |
| 107127-3 | Exercise intensity panel | 1 |
| 107129-9 | Level of exertion information panel | 1 |
| 107130-7 | Entity Multimedia file information panel | 1 |
| 107131-5 | Meds dispense info panel | 1 |
| 107138-0 | General structured lab report | 1 |
| 107147-1 | Meds safety info panel | 1 |
| 107151-3 | Inspired oxygen information panel | 1 |
| 107229-7 | Anti-hypertensive drug panel Ur | 11 |
| 107243-8 | Rh ag Cc Ee pnl RBC | 5 |
| 107288-3 | Candida sp DNA pnl Bld NAA+probe | 4 |
| 107332-9 | Goal attainment scale GAS follow-up assessment Reported | 4 |
| 107348-5 | Drug toxicology pnl Spec | 7 |
| 107555-5 | Comp C3+C4+ C1q Ab.IgG pnl SerPl | 19 |
| 107564-7 | Myositis spe Ab pnl SerPl | 14 |